



**MGM INSTITUTE OF HEALTH SCIENCES**  
**(Deemed University u/s 3 of UGC Act, 1956)**  
**Grade 'A++' Accredited by NAAC**  
**Non Government Porject**

Sr. No	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/ Co Investigator	Name of the funding agency	Type (Government/ Non-Government	Department of Pricipal Investigator/ Co- Inveatigator	Year of Award	Funds provided (INR in Lakhs)	Duration of Project
<b>2014-15</b>								
1	Validation of ingenious device designed by ACTOFIT for kinematic analysis of joint motion	Dr. Rajani Mullerpatan	ACTOFIT	Non - Government	Physiotherapy Navi Mumbai	2014	0.3	1 yrs
2	Establishment of MGM Centre of Human Movement Science at MGM School of Physiotherapy	Dr. Rajani Mullerpatan	International Society of Biomechanics	Non - Government	Physiotherapy Navi Mumbai	2014	74.6683	3 yrs
<b>2015-16</b>								
1	Non Invasive TB Triage & Patient Mapping platform using breath via Low cost titanium dioxide Nanotube sensor	Dr. Samir Pachpute (PI)	IKP Knowledge Park	Non - Government	Microbiology Navi Mumbai	2015	49.9	1 yrs
2	The effects of labour and birth positioning on pelvic dimensions: gaining further insight to improve the birth experience	Dr. Rajani Mullerpatan	Shastri foundation	Non - Government	Physiotherapy Navi Mumbai	2015	1.12	1 yrs
3	Clinical Evaluation of Breath-Based point of care test for diagnosis of Pulmonary Tuberculosis	Dr. Pradeep Potdar	University of UTAH, USA & Nanosynth	Non - Government	Respiratory Medicine	2016	66	1 yrs
4	A Randomized, Double-blind, Parallel Group Study to Evaluate the Effect and Safety of Test Biscuits as Compared to Placebo Biscuits in Regulating Blood Glucose Level in Subjects With Type 2 Diabetes Mellitus.	Dr. Deepak Bhosle	Karmik life sciences	Non - Government	Pharmacology Aurangabad	2016	3.27866	Ongoing

5	A Randomized, Double-Blind, Placebo-Controlled, Three-Arm, Parallel Group, Multi-Centric, Clinical Study To Evaluate The Therapeutic Bio-Equivalence Of Two Tacrolimus 0.1% Topical Ointment Formulations In Adult Patients With Moderate To Severe Atopic Dermatitis.	Dr. Ashish Deshmukh	Lambda Therapeutic Research Limited	Non - Government	TB & Chest Aurangabad	2016	0.9576	Ongoing
6	Arandomized, multi center, open label, two-treatment, two-period, two-sequence, multiple dose,crossover, steady state bioequivalence study of Everolimus tablets, 10 mg of Biocon Limited, India vs. Afinitor® (Everolimus) tablets, 10 mg of Novartis Phannaceuticals Corporation, USA in advanced renal cell carcinoma (RCC) patients	Dr. Chandrashekhar Tamane	Veeda Clinical Research Pvt. Ltd,	Non - Government	Oncology Aurangabad	2016	1.12928	Ongoing
<b>2016-17</b>								
1	A Randomized, Open Label, Two Period, Single Dose, Crossover, Bioavailability Study Of Paclitaxel Injection Concentrate For Nano-Dispersion (PICN) And Abraxane® In Subjects With Locally Recurrent Or Metastatic Breast Cancer.	Dr. Chandrashekhar Tamane	Sun Pharma Advanced Research Company Ltd (SPARC)	Non - Government	Oncology Aurangabad	2016	1.12928	Ongoing
2	Real world, Non-interventional, Observational Study of Hydroxyzine hydrochloride in chronic pruritus	Dr. H R Jerajani	Clinresearch Healthcare solution pvt ltd	Non - Government	Dermatology Navi Mumbai	2016	2.1	Ongoing
3	A Phase IV, Open-Label, Multi-center Study to Evaluate the Safety of Apixaban in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery. Protocol Number : CV185-158	Dr. Girish Gadekar	PPD Pharmaceutical Development India Pvt Ltd	Non - Government	Orthopaedics Aurangabad	2016	19.2	Ongoing
4	Real world, non-interventional, observational study of Venusia Max Cream as Moisturizer in Psoriasis	Dr. H R Jerajani	Bio Quest pvt ltd	Non - Government	Dermatology Navi Mumbai	2017	2.1	Ongoing
5	To evaluate efficacy and safety of Bacillus clausii (2 billion spores/5 ml) suspension as an add on therapy to standard of care in acute viral diarrhoea in children	Dr. Nimain Mohanty	Wockhardt Ltd	Non - Government	Paediatrics Navi Mumbai	2017	11.49	Ongoing

6	A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase II Study to Evaluate the Efficacy, Tolerability, and Safety of Topical Povidone-Iodine (PVP-I, 2% [W/W]) in Pediatric Subjects for the Treatment of MolluscumContagiosum.	Dr. Ashish Deshmukh	JSS Clinical Research Limited	Non - Government	TB & Chest Aurangabad	2017	3.495	Ongoing
7	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of LNP1892 (Monotherapy) in Chronic Kidney Disease (CKD) Patients with Secondary Hyperparathyroidism (SHPT), On Dialysis and Not on Dialysis. Protocol Number: LRP/LNP1892/2016/007; Version No.: 1.2, Dated 15 Dec 2016	Dr. Sudhir Kulkarni	LUPIN	Non - Government	Nephrology Aurangabad	2017	1	Ongoing
8	A rarulomized, open label, patallel-group, actjle-comparator controlled, muhi-center study to eraludte tfu efcacy lnd safety ofLllipristal acetate (5 ng tablets), as comparcdwith Leuprolide acetate (3.75 mg intramusculal injection) for 12 weeks, in the preoryratiye h,eatment of moderate to severe swptomatic uterine fibroids	Dr. Lakshmi Rachkonda	Cliantha Research Limited	Non - Government	OBGY Aurangabad	2017	0.7902	Ongoing
9	Title An open label, Two Arms, Comparaiive, Phase'IV Clinical Study evaluatLng safely and efficacy of Oratil LZ (combination of Cefuroxime 250m9 + Linezo id 600m9) versus L nezolid 600m9 in patiefts with Diabetic Foot Infectons.	Dr. Anuradha Patil	Macleods Pharmaceutical Ltd	Non - Government	Pathology	2017	1.4375	Ongoing
10	An Open Label Prospective, comparative, randomized, clinical study evaluating efficacy and safety of treatment A (Tamsulocin 0.4 mg Modified release capsule) versus treatment B (FDC Deflazacort 30 mg plus Tamsulocin 0.4 mg Tablet) in the patients with ureteral stone.	Dr. Prashant Darakh	Macleods Pharmaceutical Ltd	Non - Government	Urology Aurangabad	2017	2.4	Ongoing

11	A Two arm, Comparative, Parallel, Randomized, double-blind, double-dummy Clinical study to evaluate and compare the efficacy and safety of Cefrine (combination of cefdinir 300 mg + lactobacillus 60 million cells) Capsule versus Cefuroxime 250 mg Tablet in the treatment of patients with Upper Respiratory Tract Infections.	Dr. Rajendra Bohra	Macleods Pharmaceutical Ltd	Non - Government	ENT Aurangabad	2017	2.4	Ongoing
12	A Prospective, Multicentric, Phase IV Clinical Study evaluating safety and efficacy of Leuprorelin 3.5mg Injection plus Enzomac Tablet (Trypsin 96 mg + Bromelain 180 mg + Rutoside Trihydrate 200 mg) versus Leuproretin 3 mg Injection in the treatment of patients diagnosis with Endometriosis Protocol No.: CT-205-LEEN-2016	Dr. Swati Shiradkar	Macleods Pharmaceutical Ltd	Non - Government	Community Medicine	2017	1.725	Ongoing
13	An open label, Two arm, Comparative, Randomized Phase IV Clinical Study evaluating efficacy and safety of Alrista Forte (Epalrestat 150 Mg + Methylcobalamin 1500 Mcg + Pregabalin 150 Mg) Tablet versus Pregabalin 150 Mg Capsule in patients with Diabetic Neuropathy	Dr. Deepak Bhosle	Macleods Pharmaceutical Ltd	Non - Government	Pharmacology Aurangabad	2017	2.4	Ongoing
<b>2017-18</b>								
1	26 Week, Multicenter, randomized, placebo controlled, double blind, parallel group, phase 3 trial with a 26 week safety extension period evaluating the safety and efficacy of Dapagliflozin 5 and 10 mg and saxagliptin 2.5 and 5 mg in pediatric patients with type 2 diabetes mellitus who are between 10 and below 18 years of age	Dr. Deepak Bhosale	Astrazeneca Pharma India Ltd	Non - Government	Pharmacology Aurangabad	2017	3.77323	Ongoing

2	A 24'week, randomised, double'blind, double-dummv parallel group, multi cenire, active'controlled study to evaluatc efficacy and safety ofremogliflozin etabonate in subjects with type'2 diabetes mcllitus.	Dr. Deepak Bhosale	Glenmark Pharmaceutical Ltd	Non - Goverment	Pharmacology Aurangabad	2017	25.65	Ongoing
3	A Study to Evaluate the Effect of Dapagliflozin on Incidence of Worsening Hearl Failure or Cardiovascular Death in in Patients lvith phronic Heart Failure with Reduced Ejection F-raction.	Dr. Prashant Udgire	Astrazeneka Pharma India Ltd	Non - Goverment	Plastic Surgery Aurangabad	2017	63.3	Ongoing
4	Inj- TR2SERVE :A comprehensive program to train , triage, and improve services for unintended childhood injuries in India	Dr. Maninder singh Setia	Grand Challenges Canada	Non - Goverment	OBGY Navi Mumbai	2018	0.98545	Ongoing
5	Phase 3 Multicenter Double blind study to evaluate the long term safety and efficacy of barciunib in adult patients with atopic dermatitis	Dr. H R Jerajani	Elli Lilly Company (India) Pvt Ltd Gurgaon Haryana	Non - Goverment	Dermatology Navi Mumbai	2018	24.25868	Ongoing
6	A Multicenter Randomized double blind placebo controlled study to evaluate the efficacy and safety of baricitinib in adult patients with moderate to severe atopic dermatitis	Dr H R Jerajani	Elli Lilly Company (India) Pvt Ltd Gurgaon Haryana	Non - Goverment	Dermatology Navi Mumbai	2018	15.7825	Ongoing
<b>2018 -19</b>								
1	Biomechanical analysis and energy expenditure of traditional, chair and wall Suryanamaskar	Dr. Rajani Mullerpatan	Sancheti College of Physiotherapy	Non - Goverment	Physiotherapy Navi Mumbai	2018	0.172	1 yrs
2	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function	Dr. Prashant Udgire	Sanofi- Synthelabo Pvt Ltd	Non - Goverment	Cardiology Aurangabad	2018	112.925	Ongoing

3	A Randomized, Double-Blind, Placebo-Controlled, three-arm, Parallel Design, Multiple site, Study to Evaluate the Therapeutic equivalence and Safety of Tacrolimus Ointment, 0.1% (Encube Ethicals Private Limited) with Protopic® - (Tacrolimus Ointment 0.1% (Astellas Pharma US, Inc) in the treatment of Moderate to Severe Atopic Dermatitis.	Dr. Ashish Deshmukh	Accutest	Non - Government	Skin and VD Aurangabad	2018	10.97	Ongoing
4	A Multicentric, Open label, Randomized, Comparative, clinical study evaluating safety and Efficacy of Fixed Dose combination of Trypsin 48 mg + Bromelain 90 mg + Rutoside Trihydrate 100 mg enteric coated tablet versus Serratiopeptide 10 mg enteric coated tablet in patient for healing potential in surgical wound after minor surgery.	Dr. Mahendra Surywanshi	Macleods Pharmaceutical Ltd	Non - Government	Surgery Aurangabad	2018	2.88	Ongoing
5	A Phase III Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Centre, Multinational Study to Evaluate Efficacy and Safety of TRC150094 as an Add on to Standard of Care in Improving Cardiovascular Risk in Subjects with Diabetes, Dyslipidemia and Hypertension.	Dr. Deepak Bhosle	IQVIA HDS (India) Private	Non - Government	Pharmacology Aurangabad	2019	20.3976	Ongoing
6	Safety and Efficacy of Lipiodol® Ultra Fluid in Association with Surgical Glues during Vascular Embolization, a phase IV study.	Dr. Shivaji Pole	SIRO Clinpharm Pvt. Ltd.	Non - Government	Interventional Radiology Aurangabad	2019	10.7085	Ongoing
<b>2019 -2020</b>								
1	Rotasili ® vaccine intussusceptions surveillance in Kerala, Karnataka , Maharashtra and Gurjarat, India	Dr. Mohd Haseeb	Bill and Melinda Gates Foundation	Non- Government	Medicine	2020	383400	2 year
2	Major neurological complications following central neural blockade – A pilot study in Aurangabad city	Dr. Sadhana Kulkarni	MGM Institute of Health Sciences, Navi Mumbai (faculty project )	Non- Government	Emergency Medicine	2019	25,000	1 Year
3	Safety and Efficacy of Lipiodol Ultra fluid in association with Surgical Glues during Vascular Embolization. (IV) Protocol No: LUF-44-001	Dr Shivaji Pole, Dr Ejaj Patel	GUERBET	Non- Government	Radiology	2019	Rs.1,07,085/- (Per Patient)	180 days

4	A Multicentric, Randomized, Open label, Clinical trial To Evaluate Efficacy and Safety of Tapentadol Nasal Spray in comparison to Tramadol Immediate release Capsule and Intravenous injection in patients with Post operative moderate to severe pain. PNo: CT/TAPE/PAIN/17/03	Dr Tejendersingh Chhabda, Dr Amey Chakkarwar	SIRO CRO	Non- Government	Surgery	2019	Rs. 27,600/- (Per Patient)	180 days
5	Multi centre cross sectional epidemiological study to characterize the prevalence and distribution of lipoprotein (a) levels among patient with established cardiovascular disease P No : CTQJ23A12001	Dr Prashant Udgire	Novartis	Non- Government	Cardiology	2019	Rs 8,400/- (Per Patient)	180 days
6	A Randomized,Open label, Prospective,Comparative Multicentre, Parallel group Active controlled Phase III Study evaluate safety and efficacy of Ropivacaine readyfusor 2mg/ml versus Ropivacaine ballon pump infusor 2mg/ml as continuous surgical site infusion for treatment of post surgical Pain in lower abdominal Laprotomy. P. No:CP/04/18	Dr Vasanti Kelkar	JSS	Non- Government	Anaesthesiology	2019	Rs 8,400/- (Per Patient)	180 days
7	A Prospective, Single-center, Open-label, Randomized, Parallel group, Active-controlled Clinical Study to Evaluate the Efficacy and Safety of CefpodoximeProxetil 200 mg + Clavulanic acid 125 mg versus Amoxicillin 500 mg + Clavulanic acid 125 mg in the Treatment of Patients with Upper Respiratory Tract Infections.	Dr Rajendra Bohra	Macleods Pharmaceuticals Ltd.	Non- Government	ENT	2019	Rs 6,000/- per patient	180 days

8	A Prospective, ,Double Blind, Randomized Parallelgroup,vehicle controlled,Multicentre Clinical Study to evaluate Safety and Bioequivalence of Mupirocin Cream USP 2% (Supplied by Glasshouse Pharmaceuticals Limited Canada) using Mupirocin cream 2% (Manufactured by :Glenmark Pharmaceuticals Inc:USA) as a reference product,in subjects with secondarily Infected Traumatic Skin Lesions P.No : GH-SL-IN-01	Dr.Ashish Deshmukh	JSS	Non- Government	Dermatology	2019	Rs 15,000 per patient	180 days
9	A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease	Dr Umar Quadri	GSK/PPD	Non- Government	Emergency Medicine	2020	Rs 7,27,291/-	1 Year
10	A Phase II, controlled clinical study designed to evaluate the effect of ArtemiC in patients diagnosed with COVID-19.	Dr. Umar Quadri	Biosphere Clinical Research Pvt. Ltd	Non- Government	Emergency Medicine	2020	Rs 18,000/-	1 Year
11	A prospective, multi-centre, open label, phase IV study to evaluate safety and efficacy profile of Infimab™ in patients with moderate to severe plaque psoriasis	Dr. Ashish Deshmukh	Reliance Life Sciences	Non- Government	Dermatology & Pharmacology	2020	Rs 36,344/-	1 Year
12	An open label, randomized, active-controlled, multi-centric phase-ii/iii study in indian toddlers and infants to assess the immunogenicity and safety of siiplhexasiiltm (dtwp-hepb-ipv-hib) vaccine in comparison with siiplpentavac (dtwp-hepb-hib) + poliovac (ipv) vaccines, administered as separate injections.	Dr. Deepak Tayade	Serum Institute of India	Non- Government	Community Medicine	2020	Rs 26,300/-	1 Year
13	A randomized double blind placebo controlled study to evaluatethe efficacy and safety of cordyceps capsules ( Food supplement) as an additional on therapy in patient with mild to modrate covid -19 infection	Dr. Sagar Sinha Dr. Siddharth Dubhasi, (AIIMS, Nagpur) Dr. Jayashree Ghanekar, Dr. Sameer Kadam, Dr. Parineeta Samant	M/S Ambosia Food Farm Co. Uttrakhand	Non- Government	Emergencny Medicine , Surgery, Biochemistry and AIIMS, Nagpur	2020	14,72,000	1 Year
14	Survey to collect voice samples of patients and age matched healthy individuals P No: VoQuest01	Dr. Deepak Bhosle	Quest	Non- Government	Pharmacology	2020	Rs.100 /- (Per Patient)	180 days

15	A Multicenter, Phase III, Double-Blind, Randomized, Placebocontrolled Study To Evaluate The Efficacy Of Recombinant Bcg Vpm1002 In Reducing Infection Incidence And Disease Severity Of Sars-Cov-2/ Covid-19 Among High-Risk Subjects P No: SII-Rbcg/ COVID-19/IN-01	Dr. Deepak Tayade	Serum Institute of India Pvt. Ltd	Non- Government	Community Medicine	2020	Rs 18,200/- (Per Patient)	180 days
16	A Phase III, Multicentre, Randomized, Double Blind, Parallel group, Comparative Clinical Study to evaluate Efficacy and Safety of Ropivacaine Hydrochloride 0.75% (7.5mg/ml) in Dextrose 8% (80 mg/ml) injection compared to Bupivacaine Hydrochloride 0.5% (5mg/ml) in Dextrose 8% (80mg/ml) injection for subjects undergoing lower limb orthopedic surgeries under spinal anaesthesia P No: BCR/RPD/01	Dr. Vasanti Kelkar	Neon	Non- Government	Anaesthesiology	2020	RS 10,000/- (Per Patient)	180 days
17	A Comparative, Randomized, Two arm, Double blind, Parallel Group, Multicentre, Phase III Clinical study to Evaluate the Efficacy, Safety, and Tolerability of Netarsudil Ophthalmic Solution 0.02% vs Timolol maleate Eye drops 0.5% in treatment of elevated Intraocular Pressure (IOP) in subjects with Open Angle Glaucoma or Ocular Hypertension P No: APL/CT/18/03	Dr. Jyotika Mishrikotkar	Mediclin Clinical Research	Non- Government	Ophthalmology	2020	Rs 18,500 (Per Patient)	180 days
18	A prospective, Multicentre, Randomized, Double blind, Phase 3 study to evaluate the safety and efficacy of a gel formulation of Esmolol hydrochloride (Galnobax) in treating Diabetic Foot Ulcer P No: NG-A16	Deepak Bhosale	JSS	Non- Government	Pharmacology	2020	Rs 80,000 (Per Patient)	180 days
19	A Randomized Open-Label Study To Evaluate The Efficacy And Safety Of Favipiravir And Umifenovir As Compared To Favipiravir Alone In Moderate Hospitalized Adult Indian Covid-19 Patients P No: GPL/CT/2020/004/III	Dr. Anand Nikalje	Glenmark	Non- Government	Pharmacology	2020	Rs 95,000/- (Per Patient)	180 days
20	A Phase II, controlled clinical study designed to evaluate the effect of ArtemiC in patients diagnosed with COVID-19.	Dr. Umar Quadri	MGC Pharma	Non- Government	Emergency Medicine	2020	Rs 18,000/- per patient	180 days

21	A Randomized, Open Label, Single Centre, Observational, Prospective, Clinical Study to Evaluate the Efficacy and Safety of GanjhuVir syrup and tablet when administered along with Standard of Care (SOC) and compared against SOC in Covid-19 positive patients.	Dr.Umar Quadri	Radhika Ayurveda Research and Development	Non- Government	Emergency Medicine	2020	Rs 6,666/- per patient	180 days
22	A Randomized, Open Label, Parallel Efficacy, Active Control, Multi- Centre Exploratory Drug Trial to Evaluate Efficacy and Safety of an Ayurvedic Formulation- II (SanshamaniVati Plus) as Adjunct Treatment to Standard of Care for the management of Mild to Moderate COVID-19 Patients.	Dr. Syed Umar Qudari	AYUSH CSIR	Non- Government	Emergency Medicine	2020	Rs 15,000/- per patient	180 days
23	An open label, randomized, active-controlled, multi-centric phase-ii/iii study in indian toddlers and infants to assess the immunogenicity and safety of siiplhexasiiltm (dtwp-hepb-ipv-hib) vaccine in comparison with siiplpentavac (dtwp-hepb-hib) + poliovac (ipv) vaccines, administered as separate injections	Dr. Deepak Tayade	Serum Institute of India	Non- Government	Community Medicine	2020	Rs 26,300/- per patient	180 days
24	A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease	Dr. Umar Quadri	GSK	Non- Government	Emergency Medicine	2020	Rs 7,27,291/- per patient	180 days
2020- 2021								
1	Randomized, double-blind, placebo-controlled, parallel-group, multi-centre phaseII/III adaptive clinical trial to assess the safety and immunogenicity, of Gam-COVID-Vac combinedvector vaccine for SARS-CoV-2 infection in Indian Healthy Subjects.	Dr. Anand Nikalje	JSS Medical Research India Pvt Ltd.,	Non Government	General Medicine	2020	16	1 Year
2	Double-blind, vehicle-controlled, randomised, multi-centre study to evaluate the efficacy and safety of LH-8 cutaneous solution in children and adolescents with moderate to severe scalp Alopecia Areata.	Dr. Ashihs Deshmukh	CliniExperts Research Services Private Limited	Non Government	Dermatology	2020	2	1 Year

3	A multicenter, phase II, double blind, randomized, placebo controlled study to evaluate efficacy of recombinant BCG VPM1002 in reducing infection incidence and disease severity of SARS-COV-2/ COVID-19 among high risk subjects.	Dr. Tayade Deepak Narayan	Serum Institute of India (SII)	Non Government	Community Medicine	2020	0.5	1 year	
3	A Multicenter, Phase III, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy of Recombinant BCG VPM1002 in Reducing Infection Incidence and Disease Severity of SARS-COV-2/COVID-19 Among High-Risk Subject under.(Amended)	Dr. Tayade Deepak Narayan	DIGNOSEARCH	Non Government	Genral Medicine	2020	26.4	1 Year's	
4	Promesa DES - 1: A Prospective, Multicenter, Single arm, Open label Study to Evaluate Safety and Performance of Promesa™ DES Sirolimus Eluting Self-Expandable Nitinol Peripheral Stent System for Treating Superficial Femoral Artery (SFA) and Iliac Artery Lesions.	Dr. Shivaji Pole	Meril Life Science Pvt. Ltd.	Non Government	Radiology	2020	1.5	1 Year's	
5	Open label, Randomized, Active-controlled, Multi-centric phase II/III Study in Indian Toddlers and Infants to Assess the Immunogenicity and Safety of SIIPL HEXASIIL™ (DTwP-HepB-IPV-Hib) Vaccine in Comparison to SIIPL Pentavac (DTwP-HepB-Hib) + Poliovac (IPV) vaccines Administered.	Dr. Deepak Tyade	HEXA	Non Government	Pediatric	2020	1.9	1 Year's	
6	An open lable, randomized, active controlled, multicentric phase -II/III study in Indian toddlers and infants to assess the immunogenecity and safety of SIIPL HEXASIIL (DTwP-HepB-IPV-Hib) vaccine in comparision with SIIPL Pentavac (DTwP-HepB-Hib) and Poliovac (IPV) vaccines, administered as seperate injections	Dr. Tayade Deepak , Joshi Bhavna Engade Madhuri Joshi Pradnya, Nela Madhura	Dr. Dr. Dr. Dr.	Serum Institute of India (SII)	Non Government	Community Medicine & Pediatrics	2020	2.5	3 year
7	A prospective, multi-centre, open lable, phase IV study to evaluate safety and efficacy profile of Infimab TM in patients with moderate to severe plaque psoriasis.	Dr Ashish Deshmukh	Reliance	Non Government	Skin & VD	2020	7.3	1 year	

8	A prospective, randomized, two-arm, active-controlled, parallel, Multicentre, non-inferiority, phase III clinical trial to assess the efficacy and safety of Amorolfine lotion 0.25% W/v as compared to Amorolfine cream 0.25% w/w in patients with superficial fungal infection of the skin.	Dr Ashish Deshmukh	Zydus	Non Government	Skin & VD	2020	2.92	2 year
9	A prospective, Double-Blind, Randomized, Parallel- Group, Vehicle-controlled, Multicentre study to Evaluate the Safety and Bioequivalence of Mupirocin Cream USP 2 % (Supplied By:Glasshouse Pharmaceutical Limited Canada) using Mupirocin Cream USP 2% (Manufactured by: Glenmark Pharmaceuticals Ins; USA) as a Reference product, in subject, with Secondarily Infected Traumatic Skin Lesions.	Dr Ashish Deshmukh	JSS	Non Government	Skin & VD	2020	0.9	1 Year
10	A Phase III, Multicentric, Prospective, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Molnupiravir in Adult Indian Patients with Mild COVID-19.	Dr. Umar Quadri	Hetero Labs Limited	Non Government	General Medicine	2021	3	1 Year
11	A Phase-III, Multicenter, Prospective, Double Blind, Randomized, Parallel Clinical Study Evaluating The Efficacy, Safety And Tolerability Of Hetero-Tocilizumab In Cytokine Storm Of Severe Coronavirus Disease (Covid-19) Pneumonia (TOCICOVID Study).	Dr. Anand Nikalje	Hetero Biopharma Limited	Non Government	General Medicine	2021	23	1 Year
12	A Phase 3, Observer blind, Randomized, Active-Controlled Trial Evaluating the Immunologic Noninferiority, Safety and Tolerability of a 15-valent Pneumococcal Conjugate Vaccine Compared to a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given with Routine Pediatric Vaccinations.	Dr. Mohammed Haseeb	Tergene Biotech Pvt. Ltd	Non Government	Pediatric	2021	7	1 Year

13	A multicentre, prospective, open label, randomized comparative clinical trial to evaluate safety and efficacy of Reliance Life Sciences' Bevacizumab (R-TPR-023) plus standard of care and standard of care alone in COVID 19 Acute Respiratory Distress Syndrome (ARDS) Patients with non-invasive ventilation.	Dr. Anand Nikalje	Reliance life Sciences Pvt. Ltd	Non Government	Genral Medicine	2021	11	1 Year
14	A prospective randopmized double blind multicentric two arms phase 3 clinical trial to assess the efficacy and safety of levobupivacaine in dextrose injection Manufactured by Neon Laboratories LTD. Versus that of Bupivacaine heavy ( Bupivacaine hydrochloride in dextrose injection Manufactured by Themis Medicare LTD. for spinal Anesthesia in adult patients.	Dr. V. P. Kelkar(PI) Dr. Dhanjay Bhale	CRO- Biosphere Sponsor- Neon Laboratories	Non Government	Anaesthesia	2021	1.32	On going
15	A multicentre, prospective, open label, randomized comparative clinical trial to evaluate safety and efficacy of Reliance Life Sciences' Bevacizumab (R-TPR-023) plus standard of care and standard of care alone in COVID 19 Acute Respiratory Distress Syndrome (ARDS) Patients with non-invasive ventilation.	Dr. Anand Nikalje	Reliance Life Sciences'	Non Government	Genral Medicine	2021	11.15	1 Year's
16	AZ-C-MVL-18-101-A Prospective Randomized Double Blind Multicentric Two Arms Phase III Clinical Trial To Assess the Efficacy And safety of levobupivacaine in Dextrose injection manufactured by Neon Laboratories Ltd. Cersus that of Bupicain Heavy (Bupivacaine Hydrochloride In Dextrose Injection) Manufactured By Thmis Medicare Ltd. for Spinal Anaesthesia inb Adult Patients.	Dr. Kelkar Vasanti Prabhakar	Biosphere Clinical Research Pvt. Ltd	Non Government	Anesthesia	2021	0.5	1 Year

2021-2022								
1	Randomized double blinded placebo controlled parralal group multicenter phase II/III adaptive clinical trial to assess the safety and immunogenicity of gam-COVID-vac Combined Vector Vaccine for SARS-Cov-2 Infection in Indian Healthy Subjects	Dr. Anand Nikaje	JSS (Grapecity)	Non-Government	Medicine	2021	496059	02 Year
2	A prospective, randomized, two-arm, active-controlled, parallel, multicentre, non-inferiority, phase III clinical trial to assess the efficacy and safety of Amorolfine lotion 0.25% w/v as compared to Amorolfine cream 0.25% w/w in patients with superficial fungal infection of the skin.	Dr. Ashish Deshmukh	Zydus (Grapecity)	Non-Government	Dermatology	2021	140918 59015	01 Year
3	A randomized double blind placebo controlled study evaluating the efficacy & safety of otilimab IV in patient with severe pulmonary COVID 19 related disease.	Dr. Umar Quedri	PPD( Doclin C.)	Non-Government	Medicine	2021	20000 1367500	02 Year
4	A streamlined, multicenter, randomized, parallel group, double blind placebo controlled, superiority trial to evaluate the effect of EMPAgliflozin on hospitalization for heart failure and mortality in patients with acute myocardial infarction.	Dr. Prashant Udgire	Covance	Non-Government	Pharmacology	2021	55500	01 year
5	A Prospective, Double-blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of Mupirocin Cream USP 2%(Supplied by: Glasshouse Pharmaceuticals Limited Canada) using Mupirocin Cream USP 2% (Manufactured by: Glenmark Pharmaceuticals Inc; USA) as a Reference Product, in Subjects with Secondarily Infected Traumatic Skin Lesions	Dr. Ashish Deshmukh	JSS (Grapecity)	Non Government	Dermatology	2021	84647	2 year

6	A multicentre, single arm, phase IV clinical trial to evaluate the safety and efficacy of Itolizumab for the treatment of cytokine release syndrome (CRS) in moderate to severe acute respiratory distress syndrome (ARDS) patients due to COVID 19.	Dr. Anand Nikaje	IQVIA (Grapecity)	Non Government	Medicine	2021	153356	01 year
7	A Prospective, Multi-centre, Phase IV Study to Assess the Safety, Efficacy and Immunogenicity of BIOSULIN® 30:70 (Insulin Injection, Biphasic Isophane 100 IU/ml of M.J. Biopharm Private Limited) in Treatment of Patients Diagnosed with Type 2 Diabetes Mellitus	Dr. Umar Quadri	Abionene	Non-Government	Medicine	2021	27625	01 Year
8	A randomized double blind placebo controlled study evaluating the efficacy & safety of otilimab IV in patient with severe pulmonary COVID 19 related disease.	Dr. Umar Quadri	PPD Pharma (Docclin C.)	Non-Government	Medicine	2021	328557	02 year
9	Safety and Efficacy of Lipiodol® Ultra Fluid in Association with Surgical Glues during Vascular Embolization, a phase IV study	Dr. Shivaji Pole	Siro clinpharm (Ardent Clinical Research)	Non Government	Radiology	2021	94041	01 Year
10	A Prospective, Double-blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of Mupirocin Cream USP 2% (Supplied by: Glasshouse Pharmaceuticals Limited Canada) using Mupirocin Cream USP 2% (Manufactured by: Glenmark Pharmaceuticals Inc; USA) as a Reference Product, in Subjects with Secondarily Infected Traumatic Skin Lesions	Dr. Ashish Deshmukh	JSS (Grapecity)	Non Government	Dermatology	2021	7389	2 Year
11	A prospective, randomized, two-arm, active-controlled, parallel, multicentre, non-inferiority, phase III clinical trial to assess the efficacy and safety of Amorolfine lotion 0.25% w/v as	Dr. Ashish Deshmukh	Zydus (Grapecity)	Non Government	Dermatology	2021	10080	2 Year

12	A multicentre, phase III, double-blind, randomized, placebo controlled study to evaluate the efficacy of recombinant BCG VPM1002 in reducing infection incidence and disease severity of sars-cov-2/ covid-19 among high-risk subjects	Dr. Deepak Tayade	Serum (Dignosearch)	Non Government	Community Medicine	2021	581005.5	01 year
							13500	
							3500	
13	A prospective, randomized, two-arm, active-controlled, parallel, multicentre, non-inferiority, phase III clinical trial to assess the efficacy and safety of Amorolfine lotion 0.25% w/v as compared to Amorolfine cream 0.25% w/w in patients with superficial fungal infection of the skin.	Dr. Ashish Deshmukh	Zydus (Grapecity)	Non Government	Dermatology	2021	128250	02 year
14	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Cov-2 Infection in Indian Healthy Subjects	Dr. Anand Nikaje	JSS (Grapecity)	Non Government	Medicine	2021	630180	02 year
15	A Phase III, Multicentre, Randomized, Double Blind, Parallel group, Comparative Clinical Study to evaluate Efficacy and Safety of RopivacaineHydrochloride 0.75% (7.5mg/mL) in Dextrose 8% (80mg/mL) injection compared to Bupivacaine Hydrochloride 0.5% (5mg/mL) in Dextrose 8% (80mg/mL) injection for subjects undergoing lower limb orthopaedic surgeries under spinal anaesthesia.	Dr. Vasanti Kalkar	Bioshpere	Non Government	Anaesthesia	2021	28800	2 year
16	A prospective, multi-centre, open label, phase IV studyto evaluate safety and efficacy profile of Infimab™ inpatients with moderate to severe plaque psoriasis	Dr. Ashish Deshmukh	Reliance (Grapecity)	Non Government	Dermatology	2021	140036	01 year

17	A multicentre, single arm, phase IV clinical trial to evaluate the safety and efficacy of Itolizumab for the treatment of cytokinerelease syndrome (CRS) in moderate to severe acute respiratory distress syndrome (ARDS) patients due to COVID 19	Dr. Anand Nikaje	Biocon (Grapecity)	Non Government	Department of Medicine	2021	146795	01 year
18	Randomized double blinded placebo controlled parralal group multicenter phase II/III adaptive clinical trial to assess the safety and immunogenicity of gam-COVID-vac Combined Vector Vaccine for SARS-Cov-2 Infection in Indian Healthy Subjects	Dr. Anand Nikaje	JSS (Grapecity)	Non Government	Department of Medicine	2021	94770	01 year
19	A multicentre, phase iii, double-blind, randomized, placebo controlled study to evaluate the efficacy of recombinant BCG VPM1002 in reducing infection incidence and disease severity of Sars-Cov-2/ Covid-19 Among High-Risk Subjects	Dr. Deepak Tayade	Serum	Non Government	Community Medicine	2021	500	01 year
20	A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled study to evaluate the efficacy and safety of Ketorolac 30 mg sublingual tablet in the acute treatment of migraine headache.	Dr.Manjiri Naik	Syneos	Non Government	Medicine	2021	83333	01 year
21	RESPIRE - A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients with COVID-19	Dr, Anand Nikalje	Clinixel	Non Government	Medicine	2021	83250	01 year
22	A prospective, randomized, parallel, multicentric, phase III clinical trial to assess the efficacy and safety of Molnupiravir 800 mgcapsules and standard of care (soc) compared to standard of care (soc) only in patients with polymerase chain reaction (RT-PCR)confirmed Mild Covid-19 infection.	Dr, Anand Nikalje	Clinenfinity	Non Government	Medicine	2021	104643	01 year
23	A Phase IV, Open-Label, Multi-center Study to Evaluate the Safety of Apixaban in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery	Dr. Girish Gadekar	PPD Pharma	Non Government	Orthopedics	2021	75006	01 year

24	A prospective, multi-centre, open label, phase IV study to evaluate safety and efficacy profile of Infimab™ inpatients with moderate to severe plaque psoriasis	Dr. Ashish Deshmukh	Reliance (Grapecity)	Non Government	Dermatology	2021	376866	2 year
25	A multicentre, phase III, double-blind, randomized, placebo controlled study to evaluate the efficacy of recombinant BCG VPM1002 in reducing infection incidence and disease severity of sars-cov-2/covid-19 among high-risk subjects	Dr. Deepak Tayade	Serum (Diagnosearch)	Non Government	Community Medicine	2021	50000	2 year
26	A multicentre, phase III, double-blind, randomized, placebo controlled study to evaluate the efficacy of recombinant BCG VPM1002 in reducing infection incidence and disease severity of sars-cov-2/covid-19 among high-risk subjects	Dr. Deepak Tayade	Serum (Diagnosearch)	Non Government	Community Medicine		1118230	01 year
27	A multicentre, single arm, phase IV clinical trial to evaluate the safety and efficacy of Itolizumab for the treatment of cytokine release syndrome (CRS) in moderate to severe acute respiratory distress syndrome (ARDS) patients due to COVID 19.	Dr. Anand Nikaje	Biocon (Grapecity)	Non Government	Medicine	2021	30303	2 Year
28	A prospective, multi-centre, open label, phase IV study to evaluate safety and efficacy profile of Infimab™ inpatients with moderate to severe plaque psoriasis.	Dr. Ashish Deshmukh	Reliance (Grapecity)	Non Government	Dermatology	2021	77501	2 Year
29	A Phase-III, Multicenter, Prospective, Double Blind, Randomized, Parallel Clinical Study Evaluating The Efficacy, Safety And Tolerability Of Hetero-Tocilizumab In Cytokine Storm Of Severe Coronavirus Disease (Covid-19) Pneumonia (TOCICOVID Study)	Dr. Anand Nikaje	HETRO (Grapecity)	Non Government	Medicine	2021	1163565	2 Year
30	Safety and Efficacy of Lipiodol® Ultra Fluid in Association with Surgical Glues during Vascular Embolization, a phase IV study	Dr. Shivaji Pole	Siro clinpharm (Reliance)	Non Government	Radiology	2021	121500	2 Year



39	A Phase III Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-centre, Multinational Study to Evaluate Efficacy and Safety of TRC150094 as an Add On to Standard of Care in Improving Cardiovascular Risk in Subjects with Diabetes, Dyslipidemia and Hypertension.	Dr. Deepak Bhosle	IQVIA	Non Government	Pharmacology	2021	100000.8	1 year
40	A Phase IV, Open-Label, Multi-center Study to Evaluate the Safety of Apixaban in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery	Dr. Girish Gadekar	PPD Pharma	Non Government	Orthopedics	2021	50001	1 year

2022-2023

1	A Multidisciplinary Educational training course for physical therapists on managing common musculoskeletal pain conditions in Maharashtra, India	PI: Dr Rinkle Malani CO PI: Dr Prashant Mukkannavar Dr Tajuddin Chitapure Dr Vaibhavi Walimbe	International Association for the study of pain	Non Government	MGM School of Physiotherapy Aurangabad	2022	6.74206	1 Year
2	A phase two study to evaluate the testicular safety of a new oral drugs in adult male patient with active alcerative collitties.	Dr. Pravin Suryawanshi	Vedic Life sciences	Non Government	Surgery	2022	0.03459	1 Year
3	A Randomized, Double-Blind, Double-Dummy, Multiple-Dose, Multicenter, Three-Arm, Parallel Study to Compare the Efficacy and Safety of Pregabalin ER Tablet of Alvogen Malta (Out-Licensing) Ltd. to Placebo and Lyrica® (Pregabalin) Hard Capsule of Pfizer in Subjects with <u>Diabetic Peripheral Neuropathy</u> .	Dr. Deepak Bhosle	Cliantha	Non-Government	Pharmacology	2022	0.29174	1 year
4	A Randomized, Single Blind, Placebo Controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of Ursodiol Injection 625mg/25ml (25mg/ml) in Adults with moderate COVID 19 patients at a dose of 1750 mg/day via intravenous infusion	Dr. Rohan Gundre	Abiogenesis	Non-Government	Medicine	2022	9.01848	1 year
5	Study Title: A Randomized, Open-label, Prospective, Comparative, Multi-centre, Parallel group, Active controlled, Phase III Study to Evaluate the Efficacy and Safety of the Ropivacaine Readyfusor 2mg/ml versus Ropivacaine Balloon Pump Infusor 2mg/ml as a continuous surgical site infusion for the Treatment of Post-Surgicat Pain in lower abdominal laparotomy	Dr. Vasanti kelkar	JSS medical	Non-Government	Anaesthesia	2022	0.225	1 year
6	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with <u>Immunoglobulin A Nephropathy</u> - Study Number 417 201 00007	Dr. Sudhir Kulkarni	George	Non-Government	Nephrology	2022	1.500012	1 year
7	A randomized double blind placebo controlled study evaluating the efficacy & safety of otilimab IV in patient with severe pulmonary COVID 19 related disease.	Dr. Syed Umar Qudri	Doclin	Non-Government	medicine	2022	0.97308	1 year
8	A multicentre, phase III, double-blind, randomized, placebo controlled study to evaluate the efficacy of recombinant BCG VPM1002 in reducing infection incidence and disease severity of sars-cov-2/ covid-19 among high-risk subjects	Dr. Deepak tayade	Dignosearch	Non-Government	PCM	2022	4.81258	1 year
9	A prospective, randomized, parallel, multicentric, phase III clinical trial to assess the efficacy and safety of Molnupiravir 800 mg capsules and standard of care (soc) compared to standard of care (soc) only in patients with polymerase chain reaction (RT-PCR) confirmed Mild Covid-19 infection.	Dr. Syed Umar Qudri	Cliniinfinity	Non-Government	Medicine	2022	4.13739	1 year

10	KETO-22-002/"A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multi-Center, Bioequivalence Study with Clinical Endpoint of Ketoconazole Shampoo 2% (Test Product) Compared with Ketoconazole Shampoo 2% (Reference Product) In Human Adult Male and Female (non-pregnant) Subjects with Tinea Versicolor."	Dr.Ashish Deshmukh	Scitus pharma	Non-Government	skin	2022	0.85	1 year
11	A Prospective, Multi-centre, Active Post-Marketing Surveillance Study of Liposomal Amphotericin B (Amphonex® - Manufactured by Bharat serums and Vaccines ltd) in Patients with Invasive Fungal infection who are refractory to or intolerant of conventional Amphotericin B therapy in Real World Clinical Practice (AMBeR).	Dr.Anand Nikalje	synegene	Non-Government	Medicine	2022	0.0002	1 year
12	A Phase 3, Observer blind, Randomized, Active-Controlled Trial Evaluating the Immunologic Non-inferiority, Safety and Tolerability of a 15-valent Pneumococcal Conjugate Vaccine Compared to a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given with Routine Pediatric Vaccinations.	Dr.haseeb	Grapecity	Non-Government	Pediatrics	2022	1.02141	1 year
13	A Phase 3, Observer blind, Randomized, Active-Controlled Trial Evaluating the Immunologic Non-inferiority, Safety and Tolerability of a 15-valent Pneumococcal Conjugate Vaccine Compared to a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given with Routine Pediatric Vaccinations.	Dr.haseeb	Grapecity	Non-Government	Pulmonary	2022	0.5499	1 year
14	A Randomized, Double-blind, Parallel, Placebo Controlled, Three Arm, Multicentric Study to Evaluate the Efficacy and Safety of Ketoconazole 2% Cream of Cadila Healthcare Limited with Ketoconazole 2% Cream of Teva Pharmaceuticals USA in Subjects with Tinea Pedis.	Dr.Ashish Deshmukh	Cadila Healthcare (Clantha)	Non-Government	Dermatology	2022	1.76715	1 year
15	CPB-007-2021 CPB-009-2021 CPB-010-2021 CPB-005-2021	Dr. Sai Kumar Gowalikar	Wockhardt R & D	Non-Government		2022	1.35	1 year
16	A Prospective, Multi-centre, Active Post-Marketing Surveillance Study of Liposomal Amphotericin B (Amphonex® - Manufactured by Bharat serums and Vaccines ltd) in Patients with Invasive Fungal infection who are refractory to or intolerant of conventional Amphotericin B therapy in Real World Clinical Practice (AMBeR).	Dr.Anand Nikalje	Synegene	Non-Government	Medicine	2022	0.75	1 year
17	A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the Reference Product, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate, 80/4.5 µg per Actuation) Inhalation Aerosol (AstraZeneca, USA), in Adult Asthma Patients.	Dr.hafiz Deshmukh	Parexel	Non-Government	Pulmonary	2022	0.75	1 year
18	A Randomized Double-blind, Four-Arm Active and Placebo-controlled DoseFinding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients with Idiopathic Pulmonary Fibrosis (IPF).	Dr.hafiz Deshmukh	Novotech	Non-Government	pulmonary	2022	0.75	1 year

19	A Prospective, Multi-centre, Active Post-Marketing Surveillance Study of Liposomal Amphotericin B (Amphonex® - Manufactured by Bharat serums and Vaccines Ltd) in Patients with Invasive Fungal infection who are refractory to or intolerant of conventional Amphotericin B therapy in <u>Real World Clinical Practice (AMBeR)</u> .	Dr.Anand Nikalje	Bharat Serume Vaccine( Syngene)	Non-Government	Medicine	2022	0.3	1 year
20	An open label, randomized, active controlled, multi-centric Phase II/III, study in Indian toddlers and infants to assess the immunogenicity and safety of SIIPL HEXASIIL™ (DTwP-HepB-IPV-Hib) Vaccine in comparison with SIIPL PENTAVAC (DTwP-HepB-Hib) + Poliovac (IPV) vaccines administered as separate injections.	Dr.Deepak tayade	Serum Institute ( Diagosearch)	Non-Government	PCM	2022	0.76668	1 year
21	Randomized, Multicenter, Single-dose, Two-treatment, Single-period, Parallel, Bioequivalence Study of Mylan's Paliperidone Prolonged release Suspension for Injection, 175 mg and Janssen-Cilag's Trevicta® prolonged release suspension for injection, 175 mg in Subjects with Schizophrenia	Dr.manik Bhise	Siro clinpharm	Non-Government	Psychiatry	2022	0.85	1 year
22	International multicenter comparative prospective single-blind study of efficacy, safety, pharmacodynamics, pharmacokinetics and immunogenicity of the drug product Tenecteplase, lyophilized for solution for intravenous injection 50 mg (Pharmasyntez-Nord JSC, Russia) and the drug product Metalyse®, lyophilized for solution for intravenous injection 50 mg (Boehringer Ingelheim International GmbH, Germany) in patients with ST-segment elevation myocardial infarction (STEMI).	Dr.Prashant udgire	JSS medical /Pharmacenz	Non-Government	Cardiology	2022	0.765	1 year
23	A Randomized, Open-Label, Parallel-Group Study To Evaluate The Safety And Efficacy of Abrocitinib 100 Mg And 200 Mg Tablets In Participants Aged 12 Years And Older With Moderate To Severe Atopic Dermatitis In India."	Dr.Ashish Deshmukh	ICON	Non-Government	Dermatology	2022	0.3	1 year
24	Double-blind, vehicle-controlled, randomised, multi-centre study to evaluate the efficacy and safety of LH-8 cutaneous solution in children and adolescents with moderate to severe scalp Alopecia Areata	Dr.Ashish Deshmukh	Grapecity	Non-Government	Dermatology	2022	0.85556	1 year
25	A Randomized, Double-blind, Parallel, Placebo Controlled, Three Arm, Multicentric Study to Evaluate the Efficacy and Safety of Ketoconazole 2% Cream of Cadila Healthcare Limited with Ketoconazole 2% Cream of Teva Pharmaceuticals USA in Subjects with Tinea Pedis."	Dr.Ashish Deshmukh	Clantha	Non-Government	Dermatology	2022	0.7956	1 year
26	"A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial with a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients with Type 2 Diabetes	Dr.Deepak Bhosle	Grapecity	Non-Government	Pharmacology	2022	1.28143	1 year

27	A Randomized Double-blind, Four-Arm Active and Placebo-controlled DoseFinding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients with Idiopathic Pulmonary Fibrosis (IPF).	Dr.hafiz Deshmukh	Novotech	Non-Government	Pulmonary	2022	0.3	2 year
28	"A bioequivalence study of Levothyroxine sodium tablets 100 mcg of Wockhardt Limited, India compared with Eltroxin® 100 mcg (Levothyroxine sodium) tablets of Mercury Pharma Group Ltd., UK in healthy, adult, human subjects under fasting condition."	Sai Kumar Gowalikar	Wockhardt R & D	Non-Government	Wockhardt R & D	2022	0.3375	2 year
29	A Randomized Double-blind, Four-Arm Active and Placebo-controlled DoseFinding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients with Idiopathic Pulmonary Fibrosis (IPF).	Dr.hafiz Deshmukh	Novotech	Non-Government	Pulmonary	2022	0.3	1 year
30	KETO-22-002/ A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multi-Center, Bioequivalence Study with Clinical Endpoint of Ketoconazole Shampoo 2% (Test Product) Compared with Ketoconazole Shampoo 2% (Reference Product) In Human Adult Male and Female (non-pregnant) Subjects with Tinea Versicolor	Dr.Ashish Deshmukh	Oxygenclin	Non-Government	Dermatology	2022	1.23433	1 year
31	A Randomized, Double-blind, Parallel, Placebo Controlled, Three Arm, Multicentric Study to Evaluate the Efficacy and Safety of Ketoconazole 2% Cream of Cadila Healthcare Limited with Ketoconazole 2% Cream of Teva Pharmaceuticals USA in Subjects with Tinea Pedis.	Dr.Ashish Deshmukh	Cliantha	Non-Government	Dermatology	2022	0.0945	1 year
32	A randomized, open-label, parallel-group study to evaluate the safety and efficacy of Abrocitinib 100 mg and 200 mg tablets in participants aged 12 years and older with moderate to severe atopic dermatitis in India	Dr.Ashish Deshmukh	Abad HC & Research LLP	Non-Government	Dermatology	2022	2.27662	2 year
33	Safety and Efficacy of Transarterial Chemoembolization with Lipiodol® in the treatment of inoperable Hepatocellular Carcinoma (HCC) in Indian Patients: Phase IV Clinical Trial.	Dr.Shivaji Pole	Siro	Non-Government	Radiology	2022	0.31068	2 year

**2023-2024**

1	Evaluating the accuracy and efficacy of an indigenously developed speech-to text software (Digisehat) in general radiology reports in a hospital setting	Dr. Chandramani Pathak	Jatayu Healthcare Technologies (Mumbai)	Non Government	Biotechnology	2023	125000	<b>2 Years</b>
2	Validation of Biochemical Assays: Extraction of DNA and RNA from Clinical samples	Dr. Chandramani Pathak	MP Biomedical India Pvt. Ltd.	Non Government	Biotechnology	2023	270000	<b>2 Years</b>
3	Assessment of drug utilization patterns of oral cephalixin-clavulanic acid combination and other antibiotics for the management of surgical site infections	Dr.Abdul Qayyum Khan	Meticulous Healthcare	Non Government	Surgery	2023	31590	<b>1 Year</b>
4	A randomized, open-label, parallel-group study to evaluate the safety and efficacy of abrocitinib 100 mg and 200 mg tablets in participants aged 12 years and older with moderate to severe atopic dermatitis in India.	Dr.Ashish Deshmukh	Aurangabad Healthcare Research (SMO)	Non Government	Skin and VD	2023	227662	<b>1 Year</b>
5	A Randomized, Double-blind, Parallel, Placebo Controlled, Three Arm, Multicentric Study to Evaluate the Efficacy and Safety of Ketoconazole 2% Cream of Cadila Healthcare Limited with Ketoconazole 2% Cream of Teva Pharmaceuticals USA in Subjects with Tinea Pedis.	Dr.Ashish Deshmukh	Cliantha	Non Government	Skin and VD	2023	45000	<b>1 Year</b>
6	A prospective, interventional, open-label, phase 1a/1b, single- center, clinical study to evaluate the safety and tolerability of NV-CoV-2 Oral Syrup and Oral Gummy (Chewable gel) for oral administration in	Dr.Anand Nikalje	Karveer Meditech	Non Government	Medicine	2023	195122	<b>1 Year</b>
7	Cipla Ltd, CRD/20, A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the	Dr.Hafiz Deshmukh	Grapecity	Non Government	Pulmonary Medic	2023	83289	<b>1 Year</b>
8	Cipla Ltd, CRD/20, A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the	Dr.Hafiz Deshmukh	Grapecity	Non Government	Pulmonary Medic	2023	24863	<b>1 Year</b>

9	Cipla Ltd, CRD/20, A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the	Dr.Hafiz Deshmukh	Grapecity	Non Government	Pulmonary Medic	2023	333666	<b>1 Year</b>
10	KETO-22-002/" A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multi-Center, Bioequivalence Study with Clinical Endpoint of Ketoconazole Shampoo 2% (Test	Dr.Ashish Deshmukh	Scitus	Non Government	Skin and VD	2023	20250	<b>1 Year</b>
11	A Randomized, Double-blind, Parallel, Placebo Controlled, Three Arm, Multicentric Study to Evaluate the Efficacy and Safety of Ketoconazole 2% Cream of Cadila Healthcare Limited with Ketoconazole 2% Cream of Teva Pharmaceuticals	Dr.Ashish Deshmukh	Cliantha	Non Government	Skin and VD	2023	180000	<b>1 Year</b>
12	KETO-22-002/" A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multi-Center, Bioequivalence Study with Clinical Endpoint of Ketoconazole Shampoo 2% (Test	Dr.Ashish Deshmukh	Scitus	Non Government	Skin and VD	2023	24300	<b>1 Year</b>
13	Mozec PEB PTA PK Study: A prospective, single-arm, multi-centre, pharmacokinetic study to evaluate human pharmacokinetics of the drug, paclitaxel in MozecTM PEB for PTA	Dr. .Shivaji Pole	Ardent Clinical Research	Non Government	Interventional Radiologist	2023	389887	<b>1 Year</b>
14	KETO-22-002/" A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multi-Center, Bioequivalence Study with Clinical Endpoint of Ketoconazole Shampoo 2% (Test	Dr.Ashish Deshmukh	Oxygen Clinical Research SMO	Non Government	Skin and VD	2023	141405	<b>1 Year</b>
15	A randomized, assessor-blind,placebo controlled,multi center,clinical endpoint bioequivalence study to compare the efficacy and safety to generic fluticasone propionate inhalation aerosol USP 44	Dr.Hafiz Deshmukh	Grapecity	Non Government	Pulmonary Medic	2023	245700	<b>1 Year</b>
16	A randomized, assessor-blind,placebo controlled,multi center,clinical endpoint bioequivalence study to compare the efficacy and safety to generic fluticasone propionate inhalation aerosol USP 44	Dr.Hafiz Deshmukh	Grapecity	Non Government	Pulmonary Medic	2023	312266	<b>1 Year</b>
17	A randomized. Doubu-buno. Four-arm active and placebo-controlled dose-finding trial to evaluate efficacy. Tolerability. Safety and dose response of 100 mg in patients with idiopathic pulmonary fibrosis	Dr.Hafiz Deshmukh	Aurangabad Healthcare Research (SMO)	Non Government	Pulmonary Medic	2023	95000	<b>1 Year</b>

18	An Open label, Randomized, Active-controlled, Multi-centric Phase-II/III Study in Indian Toddlers and Infants to Assess the Immunogenicity and Safety of SIIPL HEXASIIL™ (DTwP-HepB-IPV-Hib) Vaccine in Comparison with SIIPL Pentavac (DTwP-HepB-Hib) + Poliovac (IPV) Vaccines, Administered as Separate Injections	Dr. Deepak Tayade	Diagnosearch	Non Government	Community Medicine	2023	67500	<b>1 Year</b>
19	Cipla Ltd, CRD/20, A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the Reference Product, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate, 80/4.5 µg per Actuation) Inhalation Aerosol (AstraZeneca, USA), in Adult Asthma Patients	Dr.Hafiz Deshmukh	Grapecity	Non Government	Pulmonary Medic	2023	189482	<b>1 Year</b>
20	Cipla Ltd, CRD/20, A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the	Dr.Hafiz Deshmukh	Grapecity	Non Government	Pulmonary Medic	2023	20477	<b>1 Year</b>
21	Comparative clinical evaluation of Efficacy and Safety of Clotrimazole Vaginal film vs Canesten V6 Vaginal Tablet In The Management Of Symptomatic Vulvovaginal candidiasis in non-pregnant women. - Open	Dr.Lakshmi Rachakonda	Grapecity	Non Government	OBGY	2023	171113	<b>1 Year</b>
22	Prospective, Multi-centre, Active Post-Marketing Surveillance Study of Liposomal Amphotericin B (Amphonex® - Manufactured by Bharat serums and Vaccines ltd) in Patients with Invasive Fungal infection who are refractory to or intolerant of	Dr.Anand Nikalje	Grapecity	Non Government	Medicine	2023	81907	<b>1 Year</b>
23	KETO-22-002/" A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multi-Center, Bioequivalence Study with Clinical Endpoint of Ketoconazole Shampoo 2% (Test Product) Compared with Ketoconazole Shampoo 2%	Dr.Ashish Deshmukh	Scitus	Non Government	Skin and VD	2023	41580	<b>1 Year</b>
24	KETO-22-002/" A randomized, double blind, placebo controlled, parallel design, multi-centre, bioequivalence study with clinical endpoint of ketoconazole shampoo 2% (test product) compared with ketoconazole shampoo 2%	Dr.Ashish Deshmukh	Oxygen Clinical Research SMO	Non Government	Skin and VD	2023	222430	<b>1 Year</b>

25	Cipla Ltd, CRD/20, A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the	Dr.Hafiz Deshmukh	Grapecity	Non Government	Pulmonary Medic	2023	174783	<b>1 Year</b>
26	A randomized, assessor-blind, placebo controlled, multi center, clinical endpoint bioequivalence study to compare the efficacy and safety to generic fluticasone propionate inhalation aerosol USP 44	Dr.Hafiz Deshmukh	Grapecity	Non Government	Pulmonary Medic	2023	73710	<b>1 Year</b>
27	Cipla Ltd, CRD/20, A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the	Dr.Hafiz Deshmukh	Grapecity	Non Government	Pulmonary Medic	2023	574850	<b>1 Year</b>
28	Cipla Ltd, CRD/20, A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the	Dr.Hafiz Deshmukh	Grapecity	Non Government	Pulmonary Medic	2023	37664	<b>1 Year</b>
29	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy- Study Number	Dr.Sudhir Kulkarni	George Clinical	Non Government	Nephrology	2023	47266	<b>1 Year</b>
30	Cipla Ltd, CRD/20, A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the	Dr.Hafiz Deshmukh	Grapecity	Non Government	Pulmonary Medic	2023	48350	<b>1 Year</b>
31	Cipla Ltd, CRD/20, A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the	Dr.Hafiz Deshmukh	Grapecity	Non Government	Pulmonary Medic	2023	447103	<b>1 Year</b>
32	Cipla Ltd, CRD/20, A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the	Dr.Hafiz Deshmukh	Grapecity	Non Government	Pulmonary Medic	2023	30078	<b>1 Year</b>
33	Protocol Tital : A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ABROCITINIB 100 MG AND 200 MG TABLETS IN PARTICIPANTS AGED 12 YEARS AND OLDER	Dr.Ashish Deshmukh	Aurangabad Healthcare Research (SMO)	Non Government	Skin and VD	2023	107499	<b>1 Year</b>

34	A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease.	Dr.Prashant Udgire	Novartis	Non Government	Cardiology	2023	16848	1 Year
35	A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease.	Dr.Prashant Udgire	Novartis	Non Government	Cardiology	2023	90000	1 Year
36	A randomized, double blind, three-arm, placebo controlled, parallel design, multi-center, clinical end point bioequivalence study of ketoconazole shampoo 2% (test product) compared with ketoconazole shampoo 2% (reference product) in adult subjects with tinea versicolor.	Dr.Ashuish Deshmukh	Oxygen Clinical Research SMO	Non Government	Skin and VD	2023	51675	1 Year
37	Comparative clinical evaluation of efficacy and safety of clotrimazole vaginal film vs canesten v6 vaginal tablet in the management of symptomatic vulvovaginal candidiasis in non-pregnant women. - open label, randomized, parallel, prospective, multicentric study.	Dr.Lakshmi Rachakonda	Grapecity SMO	Non Government	OBGY	2023	200363	1 Year
38	A randomized, assessor-blind, placebo controlled, multicenter, clinical endpoint bioequivalence study to compare the efficacy and safety to generic fluticasone propionate inhalation aerosol USP 44 mcg (Glenmark pharmaceutical Ltd) to flovent HFA (Fluticasone propionate inhalation aerosol) 44 mcg (GSK Group of companies) in treatment of patient with bronchial asthma.	Dr.Hafiz Deshmukh	Grapecity	Non Government	Pulmonary Medicine	2023	167310	1 Year
39	Rotasil@ vaccine impact assessment study in Kerala , Maharashtra and Gurjarat, India	Dr. Mohad Haseeb	CMC VELLOR Vellor	Non Government	Pediatrics	2023	288120	2 Years
40	Influence of expiratory yoga techniques on respiratory function, physical activity, quality of life, and length of hospital stay in patients with pleural disorders: A Randomized Controlled Trial	Shwelita Mehta Bela Agarwal	Society of Indian Physiotherapist	Non Government	MGM School of Physiotherapy Navi Mumbai	2023	15000	2 Years
41	Compare the difference between traditional surveys and drone surveys for identification of vector breeding places at high risk areas in Aurangabad city Maharashtra	Dr.Shivcharan Kantarao Kendre Dr. Shobha Banci Salve	Indian public Health Association- Maharashtra	Non Government	Department of Community, MGM Medical College, ABD	2024	15000	6 months

42	Assessment of Health Seeking Behaviour and health Profile among Transgenders in Aurangabad city - a cross sectional study	Dr. Pahune V. G. Dr. Tayade D.N Dr. Mahajan S.M. Dr Joshi B.P	Indian public Health Association- Maharashtra	Non Government	Department of Community, MGM Medical College, ABD	2023	6000	6 months
----	---	--	---	----------------	---	------	------	----------